News

The vaginal microbiome is finally getting recognized

Vaginal dysbiosis has long been a taboo subject, but studying and optimizing the vaginal microbiome could be a game changer for women’s health.
Written byHannah Thomasy, PhD
| 13 min read
A woman wearing grey holds a pink diagram of the female reproductive system.

The vaginal microbiome may play an important role in key aspects of women’s health, including susceptibility to infections and cancers.

credit: istock/Sewcream

Over the past decade, there has been an explosion of scientific research on the gut microbiome. Scientists have explored the role of this complex microbial community in just about every aspect of human health, including cancer, immune function, and even neurodegenerative disease.

By comparison, the vaginal microbiome has received very little attention, despite the prevalence of bacterial vaginosis (BV), which occurs when the vaginal microbiome shifts into a dysbiotic, or unhealthy, state. BV plagues approximately 30 percent of reproductive-age women in the United States; in some countries, more than 50 percent of women may be affected (1,2).

While many people consider the pain, burning, itching, and strong odor characteristic of BV to be merely a nuisance, this condition can have enormous effects on patients’ lives. “People will tell you that BV has destroyed their sense of intimacy with their partner and that it makes them feel ashamed. It has really destroyed their sense of well being,” said Caroline Mitchell, a reproductive biologist at Massachusetts General Hospital.

Caroline Mitchell explores whether vaginal microbiome transplants can prevent BV recurrence.
credit: MGH Photo Lab

However, the impacts of vaginal dysbiosis extend even further, with important health consequences not just for women, but for humanity as a whole. That’s because research indicates that the vaginal microbiome could influence the propagation of sexually transmitted infections (STIs), including chlamydia, gonorrhea, and human immunodeficiency virus (HIV) (3). BV has also been linked to infertility and risk of preterm birth, which is itself associated with an increased risk of lifelong cardiovascular, respiratory, and neurodevelopmental conditions in the child (4–7).

“The vaginal microbiome, one could say, is probably the most important microbiome because none of us would be here without pregnancy and birth,” said Craig Cohen, a reproductive health researcher at the University of California, San Francisco.

Despite the negative consequences of vaginal dysbiosis, much remains unknown about the disorder, and new treatments are virtually nonexistent. “The two classes of antibiotics recommended for the treatment of BV are the same two classes that were recommended in 1982,” said Mitchell. “That is atrocious.” While these antibiotics reduce symptoms in the short term, more than half of women will experience a BV recurrence (8).

“One of the reasons this field has not progressed further is that women's health is drastically underfunded,” Mitchell said. “It is really a disservice to women.”

Now, Mitchell and other dedicated scientists are hard at work expanding the understanding of the understudied vaginal microbiome. They are researching the roles of the different microbes within this community, attempting to identify the mechanisms through which they contribute to health or disease, and to figure out how bring an unhealthy microbiome back into balance.

Who’s who of the vaginal microbiome

A healthy gut microbiome contains a diverse array of microbes that can vary dramatically between individuals (9). The healthy vaginal microbiome, in contrast, is often dominated by one of four Lactobacillus species: L. crispatus, L. iners, L. paragasseri, and L. mulieris (10). Of these types, L. crispatus seems to be associated with optimal health. “Crispatus is the golden child of all the lactobaccilli,” said Melissa Herbst-Kralovetz, a vaginal microbiome researcher at the University of Arizona. A microbiota dominated by L. iners, on the other hand, has been linked to a greater risk for developing BV (11).

Melissa Herbst-Kralovetz studies how BV-associated bacteria may contribute to cancer development.
credit: University of Arizona College of Medicine – Phoenix Marketing & Communications

When the lactobaccilli lose dominance, a diverse array of anaerobic bacteria, including Gardnerella vaginalis, Fannyhessea vaginae, and Prevotella bivia, may begin to flourish and cause dysbiosis (12). However, no single microbe seems sufficient to cause BV, and many BV-associated bacteria are also found in healthy women (13).

“It’s really this polymicrobial consortium of bacteria,” said Herbst-Kralovetz. “There’s not just one agent, and it doesn't always look the same in every woman.” This makes the condition difficult to study, let alone prevent or treat.

Another difficulty in studying the vaginal microbiome is that there simply aren’t good animal models that allow scientists to test hypotheses. “Humans are the only species with a Lactobacillus-dominant vaginal microbial community,” said Mitchell. “Rats and mice in the very few rat and mouse vaginal microbiome studies have a low-diversity vaginal community, but it's mostly Streptococcus or Enterococcus, which are super different than Lactobacillus. And every nonhuman primate, from chimpanzees to rhesus macaques, has a diverse vaginal community that's much more like BV as their normal state.”

Nooks and crannies

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

  • Hannah Thomasy

    Hannah joined Drug Discovery News as an assistant editor in 2022. She earned her PhD in neuroscience from the University of Washington in 2017 and completed the Dalla Lana Fellowship in Global Journalism in 2020. Her work has appeared in The New York Times, Undark, and New Scientist. She enjoys playing soccer and hiking and hopes to be a contestant on The Great Canadian Baking Show one day. 

    View Full Profile

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D molecular visualization of a protein structure, rendered in a ribbon diagram style.
A comparative structural analysis of MC4R complexes reveals how agonist binding influences receptor conformation, ligand interactions, and complex stability.
Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.